PL3472314T3 - Przygotowanie pochodnych czynnika xa - Google Patents

Przygotowanie pochodnych czynnika xa

Info

Publication number
PL3472314T3
PL3472314T3 PL17814267T PL17814267T PL3472314T3 PL 3472314 T3 PL3472314 T3 PL 3472314T3 PL 17814267 T PL17814267 T PL 17814267T PL 17814267 T PL17814267 T PL 17814267T PL 3472314 T3 PL3472314 T3 PL 3472314T3
Authority
PL
Poland
Prior art keywords
derivatives
factor
preparation
Prior art date
Application number
PL17814267T
Other languages
English (en)
Inventor
Mark KARBARZ
Pamela B. Conley
Genmin Lu
Original Assignee
Alexion Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60663351&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3472314(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alexion Pharmaceuticals, Inc. filed Critical Alexion Pharmaceuticals, Inc.
Publication of PL3472314T3 publication Critical patent/PL3472314T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6432—Coagulation factor Xa (3.4.21.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL17814267T 2016-06-17 2017-06-19 Przygotowanie pochodnych czynnika xa PL3472314T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662351841P 2016-06-17 2016-06-17
EP17814267.5A EP3472314B1 (en) 2016-06-17 2017-06-19 Preparation of factor xa derivatives
PCT/US2017/038169 WO2017219034A2 (en) 2016-06-17 2017-06-19 Preparation of factor xa derivatives

Publications (1)

Publication Number Publication Date
PL3472314T3 true PL3472314T3 (pl) 2021-11-22

Family

ID=60663351

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17814267T PL3472314T3 (pl) 2016-06-17 2017-06-19 Przygotowanie pochodnych czynnika xa

Country Status (23)

Country Link
US (4) US10604748B2 (pl)
EP (2) EP3472314B1 (pl)
JP (3) JP6959268B2 (pl)
KR (1) KR102373215B1 (pl)
CN (2) CN116425860A (pl)
AU (2) AU2017283720B2 (pl)
BR (1) BR112018075964A2 (pl)
CA (1) CA3027457A1 (pl)
CL (2) CL2018003654A1 (pl)
CO (1) CO2019000120A2 (pl)
DK (1) DK3472314T3 (pl)
EA (1) EA037815B1 (pl)
ES (1) ES2875538T3 (pl)
HU (1) HUE054597T2 (pl)
IL (1) IL263591B2 (pl)
MX (1) MX2018015873A (pl)
PE (1) PE20190661A1 (pl)
PH (1) PH12018502614A1 (pl)
PL (1) PL3472314T3 (pl)
PT (1) PT3472314T (pl)
SG (1) SG11201810915QA (pl)
SI (1) SI3472314T1 (pl)
WO (1) WO2017219034A2 (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2607935T3 (es) * 2009-03-30 2017-04-04 Portola Pharmaceuticals, Inc. Antídotos para inhibidores del factor Xa y procedimientos de uso de los mismos
EP2948168B1 (en) * 2013-01-24 2018-07-18 Portola Pharmaceuticals, Inc. Inhibition of tissue factor pathway inhibitor with factor xa derivatives
EP3472314B1 (en) * 2016-06-17 2021-05-05 Alexion Pharmaceuticals, Inc. Preparation of factor xa derivatives
WO2019246094A1 (en) * 2018-06-19 2019-12-26 Portola Pharmaceuticals, Inc. Antidotes to factor xa inhibitors
KR102337683B1 (ko) * 2018-09-21 2021-12-13 주식회사 녹십자 고효율 항-tfpi 항체 조성물

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5189019A (en) 1990-04-23 1993-02-23 Merck & Co., Inc. Antistasin derived anticoagulant protein
US5589571A (en) 1994-10-28 1996-12-31 Cor Therapeutics, Inc. Process for production of inhibited forms of activated blood factors
JPH1066572A (ja) * 1996-08-29 1998-03-10 Showa Sangyo Co Ltd 高純度の大豆トリプシンインヒビターの製造方法
EP1259485B1 (en) 2000-02-29 2005-11-30 Millennium Pharmaceuticals, Inc. BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa
JP5227178B2 (ja) 2005-11-08 2013-07-03 ミレニアム ファーマシューティカルズ， インコーポレイテッド Ｎ−（５−クロロ−２−ピリジニル）−２−［［４−［（ジメチルアミノ）イミノメチル］ベンゾイル］アミノ］−５−メトキシ−ベンズアミド、第Ｘａ因子阻害剤の薬学的な塩および多形体
PT2915564T (pt) * 2007-09-28 2021-02-09 Alexion Pharma Inc Antídotos para inibidores do fator xa e métodos de utilização dos mesmos
US8455439B2 (en) 2008-11-14 2013-06-04 Portola Pharmaceuticals, Inc. Antidotes for factor Xa inhibitors and methods of using the same in combination with blood coagulating agents
ES2607935T3 (es) 2009-03-30 2017-04-04 Portola Pharmaceuticals, Inc. Antídotos para inhibidores del factor Xa y procedimientos de uso de los mismos
WO2011008885A1 (en) 2009-07-15 2011-01-20 Portola Pharmaceuticals, Inc. Unit dose formulation of antidotes for factor xa inhibitors and methods of using the same
US20150239929A1 (en) * 2012-06-14 2015-08-27 Portola Pharmaceuticals, Inc. Method for purification of recombinant factor xa derivatives
US20140346397A1 (en) * 2012-12-27 2014-11-27 Portola Pharmaceuticals, Inc. Compounds and methods for purification of serine proteases
EP2948168B1 (en) 2013-01-24 2018-07-18 Portola Pharmaceuticals, Inc. Inhibition of tissue factor pathway inhibitor with factor xa derivatives
CN105579468A (zh) * 2013-09-24 2016-05-11 辉瑞大药厂 包含重组人凝血因子Xa蛋白的异质性群体的组合物
CA2961739C (en) * 2014-08-20 2024-04-30 Portola Pharmaceuticals, Inc. Lyophilized formulations for factor xa antidote
EP3472314B1 (en) * 2016-06-17 2021-05-05 Alexion Pharmaceuticals, Inc. Preparation of factor xa derivatives

Also Published As

Publication number Publication date
US10954504B2 (en) 2021-03-23
US20170369862A1 (en) 2017-12-28
BR112018075964A2 (pt) 2019-04-02
US20210348149A1 (en) 2021-11-11
KR20190019134A (ko) 2019-02-26
EP3472314A4 (en) 2020-01-22
JP2019528242A (ja) 2019-10-10
EP3472314A2 (en) 2019-04-24
SI3472314T1 (sl) 2021-11-30
SG11201810915QA (en) 2019-01-30
WO2017219034A2 (en) 2017-12-21
US11845966B2 (en) 2023-12-19
CO2019000120A2 (es) 2019-03-29
IL263591A (en) 2019-02-03
KR102373215B1 (ko) 2022-03-10
CL2020001733A1 (es) 2020-09-25
HUE054597T2 (hu) 2021-09-28
CN110167575B (zh) 2024-03-15
PT3472314T (pt) 2021-06-18
US20240076642A1 (en) 2024-03-07
JP6959268B2 (ja) 2021-11-02
PE20190661A1 (es) 2019-05-08
PH12018502614A1 (en) 2019-09-30
US20200208131A1 (en) 2020-07-02
WO2017219034A3 (en) 2019-03-14
DK3472314T3 (da) 2021-07-26
AU2017283720A1 (en) 2019-01-03
AU2017283720B2 (en) 2022-11-17
IL263591B2 (en) 2023-03-01
EA037815B1 (ru) 2021-05-25
US10604748B2 (en) 2020-03-31
CA3027457A1 (en) 2017-12-21
IL263591B (en) 2022-11-01
MX2018015873A (es) 2019-08-12
AU2023200825A1 (en) 2023-03-16
EP3926044A1 (en) 2021-12-22
JP7273918B2 (ja) 2023-05-15
CL2018003654A1 (es) 2019-01-25
EP3472314B1 (en) 2021-05-05
CN116425860A (zh) 2023-07-14
JP2023086970A (ja) 2023-06-22
ES2875538T3 (es) 2021-11-10
CN110167575A (zh) 2019-08-23
JP2022000477A (ja) 2022-01-04
EA201990052A1 (ru) 2019-05-31

Similar Documents

Publication Publication Date Title
HK1255045A1 (zh) 取代的氧代吡啶衍生物
SG11201706729SA (en) Derivatives of sobetirome
IL272888B1 (en) Uses of piperidinyl-indole derivatives
IL263050B (en) History of Subtirum
IL263591A (en) Preparation of xa factor history
HK1245258A1 (zh) 新的二氟酮酰胺衍生物
ZA201602198B (en) Preparation of hydroxy-benzylbenzene derivatives
HK1257800A1 (zh) L-4-氯喹寧的治療用途
HK1250719A1 (zh) 脫氧糖胺的合成
EP3384921A4 (en) NEW USE OF THIOPEPTIN
HK1231387A1 (zh) 蔷薇色素化合物的新型用途
GB201502813D0 (en) Mesoporous materials
SG11201609739UA (en) Derivatives of dolaproine-dolaisoleuine peptides
IL255182A0 (en) History of korormicim with antibiotic use
IL249130B (en) Preparation of piperidine-4-carbothioamide
GB2564185B (en) Process for the preparation of derivatives of benzodioxole
EP3338775A4 (en) USES OF BUTYLIDENEPHTHALIDE
TH1601002304A (th) สารผสมเคลือบผง
GB201403170D0 (en) Preparation of antibacterial bisbenzimidazoles
TWM489614U (en) Structure of bathroom accessory